Introduction
The CBD market is global, but regulatory frameworks are national. The same CBD ingredient manufactured in Yunnan Province can legally reach consumers in some markets while facing enforcement risk in others. Understanding FDA (US) and EU compliance requirements is essential for any brand selling Chinese-made CBD products.
This article covers the regulatory landscape for selling Chinese-manufactured CBD in these two major markets.
—
US FDA Compliance for Chinese CBD
The Federal Framework
Current FDA position:
The FDA regulates CBD under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under current FDA policy:
- CBD is not an approved food additive
- CBD is not an approved dietary supplement ingredient
- Adding CBD to food or dietary supplements is technically illegal under current law
- FDA enforcement has been selective, focusing on egregious violations
- The regulatory landscape is evolving as FDA considers new policy approaches
What this means practically:
Many companies sell CBD food and supplement products in the US market. Some have faced enforcement action. Others operate without apparent regulatory consequences. The environment is characterized by regulatory uncertainty rather than clear prohibition.
Implications for Chinese-Made Products
Product quality matters:
FDA enforcement often focuses on products with quality problems — inaccurate CBD content, undisclosed THC, harmful contaminants. Sourcing high-quality ingredients from reputable Chinese manufacturers reduces enforcement risk.
Documentation requirements:
FDA can inspect imported CBD products at the border. Documentation should support: ingredient source (hemp-derived, THC compliant), quality verification through testing, and manufacturing compliance (GMP, quality systems).
FDA Requirements That Do Apply
Current Good Manufacturing Practice (cGMP):
Companies manufacturing, processing, packing, or holding dietary supplements must follow cGMP requirements — regardless of where ingredients are sourced. Chinese manufacturing does not exempt brands from cGMP compliance.
Labeling requirements:
FDA labeling rules apply to all CBD products sold in the US. Required elements include: supplement facts panel (when applicable), ingredient list, allergen declarations, manufacturer/distributor information, and net quantity.
Claims restrictions:
CBD products cannot make drug claims (claiming to treat, cure, or prevent diseases). Structure/function claims have a different regulatory framework.
—
EU Compliance for Chinese CBD
The Novel Food Challenge
What are Novel Foods?
The EU Novel Food Regulation (2015/2283) requires pre-market safety authorization for foods not consumed “significantly” in the EU before 1997. CBD extracts derived from hemp are classified as Novel Foods.
Current status:
No CBD extract has received full Novel Food authorization from EFSA. The industry operates in regulatory limbo — products are on the market, but their legal status is contested.
Industry response:
European CBD industry associations have submitted safety dossiers to EFSA for evaluation. The evaluation process is ongoing, with no definitive authorizations as of 2024.
Implications for Brands
For brands selling in the EU:
You are operating in a legally uncertain environment. Some products have faced market withdrawal or enforcement. Others continue to sell. The risk profile varies by country and product presentation.
For sourcing from China:
Your Chinese manufacturer should understand EU compliance requirements and provide documentation supporting compliance. But given the underlying regulatory uncertainty, even comprehensive documentation cannot eliminate Novel Food risk.
EU Quality and Safety Standards
Regardless of Novel Food status, EU products must meet:
- Food safety requirements under General Food Law
- Quality and hygiene standards throughout the supply chain
- Labeling requirements including THC content disclosure
- THC limits (0.2% maximum in food products)
—
Compliance Strategies
Ingredient Sourcing Strategy
For US market:
Source high-quality CBD ingredients with comprehensive COA documentation from accredited laboratories. Verify quality independently through testing in the US. Work with manufacturers who can provide documentation packages supporting FDA compliance.
For EU market:
Recognize that Novel Food compliance is uncertain regardless of supplier claims. Source from manufacturers with EU export experience who understand market requirements. Monitor EFSA evaluation progress and regulatory developments.
Documentation Strategy
Maintain comprehensive documentation:
- Certificates of Analysis for every batch
- Third-party testing verification
- Manufacturing compliance documentation
- Chain of custody documentation
- Product specifications and formulations
Documentation protects you:
If regulatory questions arise, comprehensive documentation demonstrates due diligence and compliance efforts.
Working With Chinese Manufacturers
Communicate requirements clearly:
Tell your supplier exactly what market your products target. Different markets require different formulations, testing, and documentation.
Verify compliance capabilities:
Ask suppliers about their experience serving your target market. Request documentation packages they have provided to other buyers for that market.
—
Conclusion
Selling Chinese-made CBD products in the US and EU involves navigating regulatory frameworks with significant uncertainty. The US FDA has not approved CBD food/supplement use but has not clearly prohibited it. The EU’s Novel Food framework creates genuine legal ambiguity.
The best strategy: source the highest-quality ingredients from reputable manufacturers, maintain comprehensive documentation, monitor regulatory developments, engage regulatory counsel for specific guidance, and accept that regulatory risk exists in both markets.
Chinese manufacturing can support compliance — but cannot eliminate regulatory uncertainty inherent in both the US and EU frameworks.
Table of Contents
